Merlin

Merlin is a tumor-suppressor protein produced by the NF2 gene that helps control cell growth, shape, and contact signaling. When the NF2 gene is mutated or deleted, merlin is lost or made non-functional, removing a key brake on cell proliferation. Loss of merlin is one of the most common molecular changes found in pleural mesothelioma tumors.

Origin

The protein was identified in 1993 by two research groups studying the gene responsible for neurofibromatosis type 2 (NF2), an inherited tumor syndrome. It was named "merlin" as an acronym for "moesin-ezrin-radixin-like protein," reflecting its structural similarity to a family of proteins that link the cell membrane to the internal cytoskeleton.

Significance in Asbestos Context

Merlin loss, caused by NF2 gene mutation or deletion, is found in roughly 40-50% of pleural mesotheliomas and is considered one of the signature molecular features of the disease. For patients, this matters in three practical ways: (1) tumor molecular testing may report NF2 status, which helps confirm the diagnosis and characterize the tumor; (2) loss of merlin activates downstream growth pathways (particularly the Hippo/YAP pathway and mTOR), which are the focus of several mesothelioma clinical trials patients may be eligible for; and (3) the molecular fingerprint of mesothelioma, including NF2/merlin loss, supports the scientific link between asbestos exposure and the specific cancer being treated, a connection that can become relevant in a legal claim.

Example Sentence

The pathology report noted loss of merlin expression and an NF2 deletion, which the oncologist explained is a common finding in asbestos-related pleural mesothelioma and made the patient a candidate for a targeted-therapy trial.

Related Terms

NF2 gene, BAP1, Hippo pathway, Tumor Suppressor Gene, Pleural Mesothelioma, Targeted Therapy

Notes

• Ask your oncologist whether your tumor has had molecular or next-generation sequencing testing, and request a copy of the report. NF2/merlin status is often included.
• If NF2 loss is documented, ask specifically about clinical trials targeting the Hippo/YAP pathway or FAK inhibitors, which are being studied in merlin-deficient mesothelioma.
• Preserve all pathology reports, molecular testing results, and tissue blocks; these records document the biological features of your cancer and can support both treatment decisions and a legal claim.
• NF2 mutations in mesothelioma tumor tissue are almost always acquired (caused by asbestos-related damage), not inherited. This is different from the NF2 syndrome that causes nervous-system tumors.